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Introduction
Soft tissue sarcomas are a rare group of malignancies of 
mesenchymal tissue origin. There are an estimated 12,000 
cases of soft tissue sarcomas diagnosed annually in the 
United States.1 These cancers are most often diagnosed in 
patients over the age of 50. However, there are specific 
subtypes, such as synovial sarcoma which can be diag-
nosed in young children. Soft tissue sarcomas can exist 
from low to high grade and may differ in their level of 
aggressiveness. Approximately 16% of patients diagnosed 
with soft tissue sarcomas will have metastatic disease at 
initial diagnosis and annually nearly 5000 patients die 
from related issues annually in the United States.1 There 
are approximately 70 different types of soft tissue sar-
coma and each is diagnosed based on a combination of 
clinical imaging, histopathologic morphology, special 
stains, and evaluation for translocations.
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Abstract
Soft tissue sarcomas are a rare group of mesenchymal malignancies which can range from low to high grade. These 
tumors have different clinical, radiographic, and histopathological characteristics. Beta human chorionic gonadotropin is 
a naturally secreted hormone by placental syncytiotrophoblast cells during pregnancy. On very rare occasions, sarcomas 
can develop the ability to ectopically produce human chorionic gonadotropin. Very few cases exist in the literature 
of soft tissue sarcomas expressing this hormone. We report the case of a 55-year-old female who presented with a 
posterior thigh soft tissue sarcoma who on the day of surgical resection was found to have an unusually elevated serum 
human chorionic gonadotropin. Positive immunohistochemical staining of the resected mass confirmed the sarcoma as 
the source of the beta human chorionic gonadotropin.
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2 Rare Tumors
With such a diversity of tumor subtypes, secretion of 
ectopic beta human chorionic gonadotropin (β-hCG) by 
the tumor is so uncommon that it is not routinely tested 
for in cases of sarcoma. A few cases have been published 
in the literature in which β-hCG was produced by sar-
coma, and most often these cases involve osteosarcoma 
instead of soft tissue sarcoma. This case report docu-
ments an unusually rare circumstance of β-hCG produc-
tion by a soft tissue sarcoma in a 55-year-old patient. We 
provide a detailed discussion of the case as well as review 
of the literature.
Case report
A 55-year-old female presented to our musculoskeletal 
oncology clinic with a chief complaint of a growing, pain-
less posterior thigh mass for approximately 6 months. We 
obtained radiographs of the femur, which demonstrated a 
soft tissue shadow in the posterior thigh with some appar-
ent calcifications within the mass (Figure 1). We then 
ordered a magnetic resonance imaging (MRI), which 
showed a large, heterogeneous soft tissue tumor abutting 
the neurovascular structures of the posterior thigh (Figures 
2 and 3). Based on the concerning imaging, we moved 
forward by obtaining a core needle biopsy of the mass. 
The biopsy findings suggested the mass to be a hyaliniz-
ing tenosynovial giant cell tumor. Because the imaging 
and clinical history did not match well with our suspicion 
that his was a soft tissue sarcoma, we decided to move 
forward with a wide excision of the tumor, prepared for 
the possibility that final pathology would prove this mass 
to be a sarcoma. On the day of the procedure, a preopera-
tive pregnancy test was ordered as is routine and the 
serum β-hCG was positive at 1122 IU/L. The patient 
reported that she was in menopause and had not had 
sexual activity in nearly a year. She denied any symptoms 
of pregnancy. The decision was made to proceed with sur-
gery, understanding that there was a possibility that the 
tumor was secreting this hormone. The tumor was resected 
with a wide margin and sent for histopathologic evalua-
tion (Figure 4). Sections from the resection specimen 
showed a proliferation of spindle cells and pleomorphic 
Figure 1. Lateral radiograph of the femur demonstrating a 
posterior thigh soft tissue shadow with internal calcifications. Figure 2. T2-weighted axial MRI of the thigh demonstrating a 
large, posterior tumor which is enhancing, heterogeneous, and 
appears to abut the neurovascular structures.
Figure 3. T2-weighted sagittal MRI of the thigh demonstrating 
a large, posterior thigh tumor which is enhancing and 
heterogeneous. Also note some proximally and distally tracking 
edema within the muscle.
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nuclei. By immunohistochemistry, there was strong stain-
ing of tumor cells for β-hCG. The morphologic and immu-
nophenotypic features were consistent with an unclassified 
pleomorphic sarcoma with ectopic β-hCG production 
(Figures 5 and 6). Unfortunately, no molecular analysis is 
available for the specimen. Postoperatively, the patient’s 
wound healed without complication, she received postop-
erative radiotherapy, and at 2 weeks postoperatively her 
β-hCG test was negative. At 1 year postoperatively, she 
was without evidence of local or metastatic disease and 
her β-hCG continued to be negative.
Discussion
Soft tissue sarcoma is a rare malignancy of mesenchymal 
tissue origin which can exist in one of nearly 70 variants. 
Each of these subtypes is diagnosed based on a combina-
tion of clinical imaging, histopathologic morphology, spe-
cial stains, and evaluation of translocations.
Although there is a great deal of diversity in these soft 
tissue tumor subtypes, secretion of ectopic β-hCG by the 
tumor is so uncommon that it is not routinely tested in 
cases of sarcoma. Very few cases have been published in 
which β-hCG was associated with a sarcoma, and most of 
these were cases involving osteosarcoma instead of soft 
tissue sarcoma. Certainly, elevated β-hCG in a 55-year-
old woman can be caused by a number of etiologies aside 
from a viable pregnancy including pituitary human chori-
onic gonadotropin (hCG) production, trophoblastic dis-
ease, phantom hCG, ectopic pregnancy, or miscarriage. 
Considering that this patient reported no sexual activity 
in over a year and she had a concerning appearing soft 
tissue mass, our clinical suspicion of a β-hCG secreting 
tumor was high.
Sarcoma and β-hCG have demonstrated some associa-
tion in the literature in regards to use as a prognostic tool as 
well as a treatment. Some authors have published that β-
hCG may function as a marker providing prognostic value 
in soft tissue tumor response.2 Other authors have investi-
gated its role in treatment. Early reports documented using 
β-hCG to treat Kaposi sarcomas with mixed outcomes but 
significant side effects.3,4 Although Kaposi sarcoma is not a 
true sarcoma, it does share many morphologic characteris-
tics with soft tissue sarcoma.
Figure 4. Clinical photograph of the tumor which was 
resected with a wide margin.
Figure 5. Sections from the resection specimen show a 
proliferation of spindle cells with admixed large polygonal cells 
with abundant pale eosinophilic cytoplasm and pleomorphic 
nuclei. There was no obvious tumor necrosis and up to 10 
mitotic figures were identified in 10 high-power fields.
Figure 6. By immunohistochemistry, there was strong staining 
of tumor cells for β-hCG without staining for desmin, smooth 
muscle actin, S100 protein, SALL4, GATA3, cytokeratin, or 
CD34. The morphologic and immunophenotypic features were 
consistent with an unclassified pleomorphic sarcoma with 
ectopic β-hCG production.
4 Rare Tumors
Among the first reports of β-hCG production from a sar-
coma was a case report published by Mack et al.5 in 1977. 
In this case, a 26-year-old male was found to have a large 
acetabular lesion. The lesion was biopsied and the results 
were inconclusive; however, a germ cell line tumor was 
suspected. Because of concern for a germ cell tumor, a 
urine pregnancy was also performed and found to be posi-
tive. An open biopsy was then performed to obtain more 
tissue and a diagnosis of chondrosarcoma was made. At the 
time of this publication, it was established that malignan-
cies could produce hormones, including β-hCG; however, 
this was the first report of a markedly elevated clinical level 
in the setting of sarcoma.
Since that first documented case, a number of other 
reports have been published. Kalra et al.6 published in 1984 
a case of an osteogenic sarcoma producing hCG in a 
22-year-old woman. In this case, pregnancy was excluded 
with a normal ultrasound as well as an endometrial curet-
tage. Tuy et al.7 in 2008 published a case report of a 37-year-
old female who presented with an aggressive appearing 
lesion of the distal femur. The patient was admitted with 
symptoms of abdominal cramping and vaginal bleeding 
and a preoperative pregnancy test was positive. Workup by 
gynecology including pelvic exam, ultrasound, and lapa-
roscopy, and dilation and curettage were negative for preg-
nancy. Workup and treatment of the femoral lesion revealed 
a high-grade osteosarcoma which stained positive for β-
hCG. Oshrine et al.8 in 2014 also reported a case of osteo-
sarcoma in an adolescent female which was secreting 
β-hCG. Serum β-hCG levels became undetectable by the 
end of her sarcoma treatment.
Due to an increasing interest in an association between 
β-hCG and sarcoma, a number of groups in 2010 began 
larger investigations. Masrouha et al.2 published in 2012 a 
study in which they retrospectively stained 37 histopathol-
ogy samples of osteosarcoma and found that five tumors 
stained positive for β-hCG. They also found that all samples 
with positive staining showed poor histological response to 
neoadjuvant chemotherapy. Lee et al.9 in 2014 performed a 
larger study and found that, in 49 pretreated osteosarcoma 
samples, 57% showed positive β-hCG expression. The group 
found no clinical difference between the tumors that stained 
positive and negative for the hormone.
In regards to soft tissue sarcomas, very few reports exist 
in the literature of tumors expressing β-hCG. The first report 
by Meredith et al.10 was published on a case of leiomyosar-
coma of the small intestine producing β-hCG in a 22-year-
old female in 1986. This patient presented with symptoms of 
nausea and vomiting, which can be commonplace during 
pregnancy. A mass was eventually appreciated and elevated 
β-hCG levels were localized to the sarcoma cells upon resec-
tion. Certainly, in a 22-year-old female, the other causes of 
elevated β-hCG previously mentioned should be at the top of 
the initial differential. Another report of a leiomyosarcoma 
secreting β-hCG was published by Mansi et al.11 in 2002. In 
this report, the patient was a 57-year-old male with a 30-cm 
retroperitoneal mass which tested positive for the hormone 
after resection. A case report by Steffensen et al.12 in 2008 
documented an epithelioid sarcoma which was metastatic to 
the placenta during pregnancy. They noted that only 8% of 
malignancies which metastasize to products of conception 
prove to be sarcoma. It is even more rare for these metastases 
to express β-hCG, as this case did. Inoue et al.13 reported in 
2011 a case of a nonrhabdomyosarcoma soft tissue sarcoma 
in a 3-month-old with a large back mass. Unfortunately, due 
to subtotal resection and chemotherapy resistance, the tumor 
progressed and this patient died of disease at 22 months old. 
Finally, Stevens et al.14 reported in 2013 a case of synovial 
sarcoma in the hip of a 45-year-old female. The author noted 
a significant delay in diagnosis due to consideration of more 
common etiologies of the elevated hormone including 
ectopic pregnancy and a trophoblastic neoplasm. At the time 
of final diagnosis, the pelvic sarcoma was deemed unresect-
able and she was treated with chemotherapy and radiation.
β-hCG expression by sarcomas is incredibly rare as has 
been evident by the scarcity of literature and case reports of 
the subject. It does seem that osteosarcoma may more com-
monly express this hormone than its soft tissue counterpart. 
Although some authors have looked into the prognostic and 
therapeutic aspects of the hormone in sarcoma, no defini-
tive outcome has been established. The most significant 
point to be taken from the few case reports published on the 
occurrence would be that it is a possibility. Especially, in 
cases of very low likelihood of pregnancy such as our 
patient, the surgeon should always consider the possibility 
that the malignancy has developed the ability to secrete the 
hormone β-hCG. We recommend in cases of a positive pre-
operative pregnancy test, in the setting of known or likely 
malignancy, a candid discussion with the patient as well as 
consult to gynecology and pelvic ultrasound if necessary.
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